| Stereochemistry | ABSOLUTE |
| Molecular Formula | C89H99Cl2N9O33 |
| Molecular Weight | 1893.685 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 23 / 23 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]%14(O[C@H]1[C@@H]2NC(=O)[C@]([H])(NC(=O)[C@]3([H])NC(=O)[C@@]4([H])NC(=O)[C@@H](CC5=CC=C(OC6=C(O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7NC(=O)CCCCCCCC(C)C)C(OC8=C(Cl)C=C1C=C8)=CC3=C6)C(Cl)=C5)NC(=O)[C@H](N)C9=CC(OC%10=CC4=CC(O)=C%10)=C(O)C=C9)C%11=CC(=C(O)C=C%11)C%12=C(C=C(O)C=C%12O[C@H]%13O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%13O)[C@H](NC2=O)C(O)=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%14NC(C)=O
InChI
InChIKey=FHBQKTSCJKPYIO-RLDSMAAISA-N
InChI=1S/C89H99Cl2N9O33/c1-34(2)9-7-5-4-6-8-10-61(109)95-69-75(114)72(111)59(32-102)130-88(69)133-79-56-26-41-27-57(79)127-53-18-14-39(24-48(53)91)78(132-87-68(93-35(3)104)74(113)71(110)58(31-101)129-87)70-85(122)99-67(86(123)124)46-29-43(106)30-55(128-89-77(116)76(115)73(112)60(33-103)131-89)62(46)45-23-38(13-15-50(45)107)64(82(119)100-70)97-84(121)66(41)98-83(120)65-40-21-42(105)28-44(22-40)125-54-25-37(12-16-51(54)108)63(92)81(118)94-49(80(117)96-65)20-36-11-17-52(126-56)47(90)19-36/h11-19,21-30,34,49,58-60,63-78,87-89,101-103,105-108,110-116H,4-10,20,31-33,92H2,1-3H3,(H,93,104)(H,94,118)(H,95,109)(H,96,117)(H,97,121)(H,98,120)(H,99,122)(H,100,119)(H,123,124)/t49-,58-,59-,60-,63-,64-,65+,66-,67+,68-,69-,70+,71-,72-,73-,74-,75-,76+,77+,78-,87+,88+,89+/m1/s1
| Molecular Formula | C89H99Cl2N9O33 |
| Molecular Weight | 1893.685 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 23 / 23 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
TEICOPLANIN A2-5 is a component of a teicoplanin complex antibiotic, which consist of six closely related glycopeptide subcomponents. TEICOPLANIN A2-5 being the most lipophilic in protein binding. Bacteria treated with the drug failed to incorporate GlcNAc, a peptidoglycan precursor, whereas they continued to synthesize DNA, RNA, and protein. The cell wall inhibition was accompanied by an accumulation of UDP-MurNAc-pentapeptide, thus indicating that the antibiotic interferes with the polymerization of the peptidoglycan but not with the synthesis of soluble precursors. Teicoplanin is indicated in adults and in children from birth for the parenteral treatment of the following infections: complicated skin and soft tissue infections; bone and joint infections; complicated urinary tract infections; infective endocarditis; bacteraemia that occurs in association with any of the indications listed above. The following side-effects may occur: nausea, vomiting, diarrhea and stomach pain, skin rash and pruritus, bronchospasm, renal impairment. Teicoplanin should be administrated with caution in patients receiving concurrent nephrotoxic or ototoxic drugs, such as aminoglycosides, amphotericin B, cyclosporine and frusemide.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Urinary tract infections, skin and soft tissue infections. Loading dose: single injection of 400 mg on the first day; Maintenance dose: single injection of 200 mg/ml daily.
Endocarditis, septicemia, joint and bone infections. Loading dose: for the first three doses – 400 mg every 12 hours; Maintenance dose: single injection of 400 mg daily.
An intramuscular injection of Targocid should not exceed 3 ml (400 mg) at a single site.
Route of Administration:
Other
Minimal inhibitory concentration (MIC) was read as the lowest concentration, which showed no visible growth after 18-24 h incubation at 37° C. The obtained results are: Staphylococcus aureus – 0.2-0.8 ug/ml, Staphylococcus epidermidis – 0.2-0.8 ug/ml, Streptococcus pyogenes – 0.006-0.05 ug/ml, Streptococcus pneumoniae – 0.05-0.1 ug/ml, Streptococcus faecalis – 0.1-0.4 ug/ml, Streptococcus mitis – 0.025 ug/ml, Streptococcus solivarius – 0.05 ug/ml, Streptococcus sanguis – 0.05 ug/ml, Streptococcus bovis – 0.4 ug/ml, Streptococcus agalactiae – 0.1 ug/ml.